New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia

Current Opinion in Hematology

Volumn 20, Issue 2, 2013, Pages 93-99

  Mattison, Ryan J ^a   Luger, Selina M ^b   Lazarus, Hillard M ^c  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute myeloid leukemia; enzymatic amplification staining; molecular imaging; nadir marrow

Indexed keywords

CYTARABINE; FLUORINE 18;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW APLASIA; BONE MARROW BIOPSY; CANCER REGRESSION; CANCER SURVIVAL; CELL METABOLISM; CONSOLIDATION CHEMOTHERAPY; DRUG MEGADOSE; FLOW CYTOMETRY; HUMAN; LONG TERM CARE; MINIMAL RESIDUAL DISEASE; MOLECULAR IMAGING; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS; BIOPSY; BONE MARROW CELLS; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS;

EID: 84873410374     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32835d8207     Document Type: Review

References (26)

1. National Comprehensive Cancer Network. Acute myeloid leukeima. Version 2.2012. http://www.nccn.org/professionals/physician-gls/pdf/aml.pdf [Accessed on 26 September 2012]
2. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21:4642-4649.
3. Liso V, Albano F, Pastore D, et al. Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia. Haematologica 2000; 85:1285-1290.
4. Hussein K, Jahagirdar B, Gupta P, et al. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia. Am J Hematol 2008; 83:446-450.
5. Yanada M, Borthakur G, Ravandi F, et al. Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. Haematologica 2008; 93:1263-1265.
6. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93:4116-4124.
7. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101:64-70.
8. Xiao Z, Xue H, Li R, et al. The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia. Am J Hematol 2008; 83:203-205.
9. Rumke CL. Imprecision of ratio-derived differential leukocyte counts. Blood Cells. 1985; 11:311-314.
10. Heil G, Krauter J, Raghavachar A, et al. Risk-adapted induction and consolidation therapy in adults with de novo AML aged
11. Rowe JM, Kim HT, Cassileth PA, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer 2010; 116:5012-5021.
12. van der Velden VH, van der Sluijs-Geling A, Gibson BE, et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010; 24:1599-1606.
13. Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012; 119:332-341.
14. DiNardo CD, Luger SM. Beyond morphology: minimal residual disease detection in acute myeloid leukemia. Curr Opin Hematol 2012; 19:82-88.
15. Perea G, Lasa A, Aventin A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 2006; 20:87-94.
16. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011; 29:495-503.
17. Corbacioglu A, Scholl C, Schlenk RF, et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 2010; 28:3724-3729.
18. Kronke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 2011; 29:2709-2716.
19. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009; 27:5195-5201.
20. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010; 11:543-552.
21. Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 2010; 116:2295-2303.
22. Lazarus HM, Sommers SR, Arfons LM, et al. Spontaneous autologous graftversus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts. Biol Blood Marrow Transplant 2011; 17:970-978.
23. Kaplan D, Kaye N, Liu F, et al. The functional duality of HoxB4 in hematopoietic reconstituting cells. Cytometry Part A: J Int Soc Anal Cytol 2013; 83:127-133.
24. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4:1334-1336.
25. Garcia C, Gebhart G, Flamen P. New PET imaging agents in the management of solid cancers. Curr Opin Oncol 2012; 24:748-755.
26. Vanderhoek M, Juckett MB, Perlman SB, et al. Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging. Leuk Res 2011; 35:310-316.